Insider Trades181 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 500 | $75.48 | $1.6B | -29.38% | +0.88% | $37.7K | -0.67% | 10b5-1 | Sell Now |
| Aug 10, 2026 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 3,162 | $77.00 | $1.6B | -29.38% | +0.88% | $243.5K | -4.02% | — | Sell Now |
| Jul 29, 2026 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 2,850 | $81.36 | $1.6B | -29.38% | +0.88% | $231.9K | -1.61% | 10b5-1 | Sell Now |
| Jul 18, 2026 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 2,466 | $79.20 | $1.6B | -29.38% | +0.88% | $195.3K | -3.19% | — | Sell Now |
| Jul 13, 2026 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 500 | $81.84 | $1.6B | -29.38% | +0.88% | $40.9K | -0.64% | 10b5-1 | Sell Now |
| Jul 2, 2026 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 6,626 | $67.75 | $1.6B | -29.38% | +0.88% | $448.9K | +0.00% | 10b5-1 | Sell Now |
| Jun 29, 2026 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 2,850 | $84.12 | $1.6B | -29.38% | +0.88% | $239.7K | -1.58% | 10b5-1 | Sell Now |
| Jun 12, 2026 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 500 | $82.03 | $1.6B | -29.38% | +0.88% | $41.0K | -0.64% | 10b5-1 | Sell Now |
| Jun 5, 2026 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 6,624 | $64.75 | $1.6B | -29.38% | +0.88% | $428.9K | +0.00% | 10b5-1 | Sell Now |
| May 13, 2026 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 500 | $78.16 | $1.6B | -29.38% | +0.88% | $39.1K | -0.63% | 10b5-1 | Sell Now |
| May 12, 2026 | Sell | ANIP | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | 459 | $79.21 | $1.6B | -29.38% | +0.88% | $36.4K | -1.19% | — | Sell Now |
| May 12, 2026 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 2,772 | $79.50 | $1.6B | -29.38% | +0.88% | $220.4K | -3.40% | — | Sell Now |
| May 11, 2026 | Sell | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 55,000 | $77.57 | $1.6B | -29.38% | +0.88% | $4.3M | -13.58% | — | Sell Now |
| Apr 13, 2026 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 500 | $77.95 | $1.6B | -29.38% | +0.88% | $39.0K | -0.63% | 10b5-1 | Sell Now |
| Mar 13, 2026 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 500 | $72.62 | $1.6B | -29.38% | +0.88% | $36.3K | -0.63% | 10b5-1 | Sell Now |
| Mar 13, 2026 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 3,162 | $71.64 | $1.6B | -29.38% | +0.88% | $226.5K | -3.35% | 10b5-1 | Sell Now |
| Mar 11, 2026 | Sell | ANIP | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | 4,772 | $74.91 | $1.6B | -29.38% | +0.88% | $357.5K | -10.97% | — | Sell Now |
| Mar 7, 2026 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 3,314 | $74.04 | $1.6B | -29.38% | +0.88% | $245.4K | -3.91% | — | Sell Now |
| Mar 7, 2026 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 5,150 | $74.04 | $1.6B | -29.38% | +0.88% | $381.3K | -2.78% | — | Sell Now |
| Mar 7, 2026 | Sell | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 17,060 | $74.04 | $1.6B | -29.38% | +0.88% | $1.3M | -4.04% | — | Sell Now |
| Mar 6, 2026 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 6,572 | $74.33 | $1.6B | -29.38% | +0.88% | $488.5K | -5.69% | 10b5-1 | Sell Now |
| Mar 6, 2026 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 9,037 | $74.14 | $1.6B | -29.38% | +0.88% | $670.0K | -2.98% | 10b5-1 | Sell Now |
| Mar 5, 2026 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 10,624 | $67.40 | $1.6B | -29.38% | +0.88% | $716.0K | -0.69% | — | Sell Now |
| Mar 3, 2026 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 2,060 | $76.50 | $1.6B | -29.38% | +0.88% | $157.6K | -2.37% | — | Sell Now |
| Mar 2, 2026 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 417 | $74.00 | $1.6B | -29.38% | +0.88% | $30.9K | -0.40% | 10b5-1 | Sell Now |
| Feb 26, 2026 | Buy | ANIP | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | 6,649 | $76.84 | $1.6B | -29.38% | +0.88% | $510.9K | +6.56% | — | Sell Now |
| Feb 26, 2026 | Buy | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 11,116 | $77.15 | $1.6B | -29.38% | +0.88% | $857.6K | +12.36% | — | Sell Now |
| Feb 26, 2026 | Buy | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 12,365 | $76.74 | $1.6B | -29.38% | +0.88% | $948.9K | +8.46% | — | Sell Now |
| Feb 26, 2026 | Buy | ANIP | Chad Gassert | SVP - CORP. DEV. & STRATEGY | 13,337 | $76.61 | $1.6B | -29.38% | +0.88% | $1.0M | +6.21% | — | Sell Now |
| Feb 26, 2026 | Buy | ANIP | Ori Gutwerg | SVP, GENERICS | 15,190 | $76.67 | $1.6B | -29.38% | +0.88% | $1.2M | +6.51% | — | Sell Now |
| Feb 26, 2026 | Buy | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 15,450 | $76.82 | $1.6B | -29.38% | +0.88% | $1.2M | +8.28% | — | Sell Now |
| Feb 26, 2026 | Buy | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 23,527 | $76.84 | $1.6B | -29.38% | +0.88% | $1.8M | +9.99% | — | Sell Now |
| Feb 26, 2026 | Buy | ANIP | Stephen P. Carey | SVP & CFO | 25,006 | $76.79 | $1.6B | -29.38% | +0.88% | $1.9M | +5.37% | — | Sell Now |
| Feb 26, 2026 | Buy | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 87,809 | $76.70 | $1.6B | -29.38% | +0.88% | $6.7M | +7.99% | — | Sell Now |
| Feb 20, 2026 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 5,323 | $78.02 | $1.6B | -29.38% | +0.88% | $415.3K | -5.90% | 10b5-1 | Sell Now |
| Feb 19, 2026 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 3,814 | $77.74 | $1.6B | -29.38% | +0.88% | $296.5K | -3.66% | 10b5-1 | Sell Now |
| Feb 12, 2026 | Sell | ANIP | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | 1,051 | $77.00 | $1.6B | -29.38% | +0.88% | $80.9K | -1.35% | — | Sell Now |
| Feb 12, 2026 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 2,470 | $77.04 | $1.6B | -29.38% | +0.88% | $190.3K | -2.25% | — | Sell Now |
| Feb 12, 2026 | Sell | ANIP | Chad Gassert | SVP - CORP. DEV. & STRATEGY | 3,325 | $77.04 | $1.6B | -29.38% | +0.88% | $256.2K | -2.43% | — | Sell Now |
| Feb 12, 2026 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 3,663 | $77.04 | $1.6B | -29.38% | +0.88% | $282.2K | -2.32% | — | Sell Now |
| Feb 12, 2026 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 3,813 | $77.02 | $1.6B | -29.38% | +0.88% | $293.7K | -1.81% | 10b5-1 | Sell Now |
| Feb 12, 2026 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 5,277 | $77.01 | $1.6B | -29.38% | +0.88% | $406.4K | -1.52% | — | Sell Now |
| Feb 12, 2026 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 12,608 | $76.74 | $1.6B | -29.38% | +0.88% | $967.6K | -4.27% | 10b5-1 | Sell Now |
| Feb 12, 2026 | Sell | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 21,986 | $77.01 | $1.6B | -29.38% | +0.88% | $1.7M | -2.93% | — | Sell Now |
| Feb 11, 2026 | Sell | ANIP | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | 1,762 | $76.25 | $1.6B | -29.38% | +0.88% | $134.4K | -4.31% | — | Sell Now |
| Feb 11, 2026 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 2,898 | $76.25 | $1.6B | -29.38% | +0.88% | $221.0K | -3.12% | — | Sell Now |
| Feb 11, 2026 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 3,011 | $76.25 | $1.6B | -29.38% | +0.88% | $229.6K | -4.05% | — | Sell Now |
| Feb 11, 2026 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 3,017 | $76.25 | $1.6B | -29.38% | +0.88% | $230.0K | -5.15% | — | Sell Now |
| Feb 11, 2026 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 4,267 | $76.25 | $1.6B | -29.38% | +0.88% | $325.4K | -5.08% | — | Sell Now |
| Feb 11, 2026 | Sell | ANIP | Chad Gassert | SVP - CORP. DEV. & STRATEGY | 4,269 | $76.25 | $1.6B | -29.38% | +0.88% | $325.5K | -5.80% | — | Sell Now |
| Feb 11, 2026 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 4,546 | $76.25 | $1.6B | -29.38% | +0.88% | $346.6K | -4.24% | — | Sell Now |
| Feb 11, 2026 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 5,503 | $76.25 | $1.6B | -29.38% | +0.88% | $419.6K | -3.04% | — | Sell Now |
| Feb 11, 2026 | Sell | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 30,659 | $76.25 | $1.6B | -29.38% | +0.88% | $2.3M | -7.46% | — | Sell Now |
| Jan 13, 2026 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 500 | $84.33 | $1.6B | -29.38% | +0.88% | $42.2K | -0.67% | 10b5-1 | Sell Now |
| Dec 18, 2025 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 1,622 | $82.40 | $1.6B | -29.38% | +0.88% | $133.7K | -2.69% | 10b5-1 | Sell Now |
| Dec 12, 2025 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 400 | $82.32 | $1.6B | -29.38% | +0.88% | $32.9K | -0.53% | 10b5-1 | Sell Now |
| Nov 13, 2025 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 400 | $87.27 | $1.6B | -29.38% | +0.88% | $34.9K | -0.53% | 10b5-1 | Sell Now |
| Nov 12, 2025 | Sell | ANIP | Chad Gassert | SVP - CORP. DEV. & STRATEGY | 14,736 | $89.06 | $1.6B | -29.38% | +0.88% | $1.3M | -4.44% | — | Sell Now |
| Oct 13, 2025 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 400 | $90.09 | $1.6B | -29.38% | +0.88% | $36.0K | -0.53% | 10b5-1 | Sell Now |
| Sep 19, 2025 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 1,000 | $98.04 | $1.6B | -29.38% | +0.88% | $98.0K | -1.63% | 10b5-1 | Sell Now |
| Sep 12, 2025 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 400 | $98.42 | $1.6B | -29.38% | +0.88% | $39.4K | -0.52% | 10b5-1 | Sell Now |
| Sep 12, 2025 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 1,710 | $97.71 | $1.6B | -29.38% | +0.88% | $167.1K | -2.72% | — | Sell Now |
| Aug 22, 2025 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 1,763 | $91.10 | $1.6B | -29.38% | +0.88% | $160.6K | -2.73% | — | Sell Now |
| Aug 20, 2025 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 100,000 | $90.36 | $1.6B | -29.38% | +0.88% | $9.0M | -9.83% | — | Sell Now |
| Aug 15, 2025 | Sell | ANIP | Chad Gassert | SVP - CORP. DEV. & STRATEGY | 20,000 | $86.97 | $1.6B | -29.38% | +0.88% | $1.7M | -10.35% | — | Sell Now |
| Aug 14, 2025 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 100,000 | $88.25 | $1.6B | -29.38% | +0.88% | $8.8M | -8.22% | — | Sell Now |
| Aug 13, 2025 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 400 | $88.87 | $1.6B | -29.38% | +0.88% | $35.5K | -0.52% | 10b5-1 | Sell Now |
| Aug 12, 2025 | Sell | ANIP | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | 4,975 | $85.71 | $1.6B | -29.38% | +0.88% | $426.4K | -10.87% | — | Sell Now |
| Aug 12, 2025 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 5,873 | $86.53 | $1.6B | -29.38% | +0.88% | $508.2K | -6.53% | — | Sell Now |
| Aug 12, 2025 | Sell | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 56,960 | $85.93 | $1.6B | -29.38% | +0.88% | $4.9M | -12.17% | — | Sell Now |
| Aug 12, 2025 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 100,000 | $66.28 | $1.6B | -29.38% | +0.88% | $6.6M | +0.00% | — | Sell Now |
| Jul 18, 2025 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 2,071 | $66.30 | $1.6B | -29.38% | +0.88% | $137.3K | -2.62% | — | Sell Now |
| Jul 14, 2025 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 400 | $64.88 | $1.6B | -29.38% | +0.88% | $26.0K | -0.50% | 10b5-1 | Sell Now |
| Jun 13, 2025 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 400 | $61.37 | $1.6B | -29.38% | +0.88% | $24.5K | -0.50% | 10b5-1 | Sell Now |
| May 15, 2025 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 881 | $60.07 | $1.6B | -29.38% | +0.88% | $52.9K | -0.97% | — | Sell Now |
| May 14, 2025 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 4,000 | $60.45 | $1.6B | -29.38% | +0.88% | $241.8K | -3.59% | — | Sell Now |
| May 13, 2025 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 400 | $62.20 | $1.6B | -29.38% | +0.88% | $24.9K | -0.50% | 10b5-1 | Sell Now |
| May 9, 2025 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 700 | $76.83 | $1.6B | -29.38% | +0.88% | $53.8K | -0.11% | 10b5-1 | Sell Now |
| Apr 14, 2025 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 400 | $68.96 | $1.6B | -29.38% | +0.88% | $27.6K | -0.50% | 10b5-1 | Sell Now |
| Mar 23, 2025 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 6,210 | $64.26 | $1.6B | -29.38% | +0.88% | $399.1K | -3.32% | — | Sell Now |
| Mar 23, 2025 | Sell | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 17,455 | $64.26 | $1.6B | -29.38% | +0.88% | $1.1M | -3.59% | — | Sell Now |
| Mar 19, 2025 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 1,866 | $65.00 | $1.6B | -29.38% | +0.88% | $121.3K | -2.80% | 10b5-1 | Sell Now |
| Mar 13, 2025 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 400 | $63.33 | $1.6B | -29.38% | +0.88% | $25.3K | -0.49% | 10b5-1 | Sell Now |
| Mar 7, 2025 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 1,000 | $60.86 | $1.6B | -29.38% | +0.88% | $60.9K | -1.48% | 10b5-1 | Sell Now |
| Mar 7, 2025 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 2,874 | $60.62 | $1.6B | -29.38% | +0.88% | $174.2K | -2.52% | — | Sell Now |
| Mar 7, 2025 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 3,314 | $60.62 | $1.6B | -29.38% | +0.88% | $200.9K | -3.52% | — | Sell Now |
| Mar 7, 2025 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 5,150 | $60.62 | $1.6B | -29.38% | +0.88% | $312.2K | -2.68% | — | Sell Now |
| Mar 7, 2025 | Sell | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 17,060 | $60.62 | $1.6B | -29.38% | +0.88% | $1.0M | -3.39% | — | Sell Now |
| Mar 5, 2025 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 5,684 | $58.50 | $1.6B | -29.38% | +0.88% | $332.5K | -1.63% | — | Sell Now |
| Feb 28, 2025 | Sell | ANIP | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | 627 | $61.89 | $1.6B | -29.38% | +0.88% | $38.8K | -1.36% | — | Sell Now |
| Feb 28, 2025 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 1,099 | $61.89 | $1.6B | -29.38% | +0.88% | $68.0K | -1.34% | — | Sell Now |
| Feb 28, 2025 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 1,099 | $61.89 | $1.6B | -29.38% | +0.88% | $68.0K | -1.60% | — | Sell Now |
| Feb 28, 2025 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 1,275 | $61.89 | $1.6B | -29.38% | +0.88% | $78.9K | -1.10% | — | Sell Now |
| Feb 28, 2025 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 1,570 | $61.89 | $1.6B | -29.38% | +0.88% | $97.2K | -1.56% | — | Sell Now |
| Feb 28, 2025 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 1,861 | $61.89 | $1.6B | -29.38% | +0.88% | $115.2K | -0.96% | — | Sell Now |
| Feb 28, 2025 | Sell | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 12,216 | $61.89 | $1.6B | -29.38% | +0.88% | $756.0K | -2.37% | — | Sell Now |
| Feb 21, 2025 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 1,000 | $60.20 | $1.6B | -29.38% | +0.88% | $60.2K | -1.44% | 10b5-1 | Sell Now |
| Feb 14, 2025 | Sell | ANIP | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | 582 | $58.92 | $1.6B | -29.38% | +0.88% | $34.3K | -1.25% | — | Sell Now |
| Feb 14, 2025 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 1,196 | $58.92 | $1.6B | -29.38% | +0.88% | $70.5K | -1.69% | — | Sell Now |
| Feb 14, 2025 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 1,730 | $58.92 | $1.6B | -29.38% | +0.88% | $101.9K | -0.88% | — | Sell Now |
| Feb 14, 2025 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 2,593 | $58.92 | $1.6B | -29.38% | +0.88% | $152.8K | -1.26% | — | Sell Now |
| Feb 14, 2025 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 2,657 | $58.92 | $1.6B | -29.38% | +0.88% | $156.6K | -1.13% | — | Sell Now |
| Feb 14, 2025 | Sell | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 7,799 | $58.92 | $1.6B | -29.38% | +0.88% | $459.5K | -1.49% | — | Sell Now |
| Feb 13, 2025 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 1,834 | $59.06 | $1.6B | -29.38% | +0.88% | $108.3K | -1.10% | 10b5-1 | Sell Now |
| Jan 13, 2025 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 400 | $53.92 | $1.6B | -29.38% | +0.88% | $21.6K | -0.71% | 10b5-1 | Sell Now |
| Dec 17, 2024 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 7,500 | $55.79 | $1.6B | -29.38% | +0.88% | $418.4K | -4.63% | — | Sell Now |
| Dec 13, 2024 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 250 | $56.24 | $1.6B | -29.38% | +0.88% | $14.1K | -0.44% | 10b5-1 | Sell Now |
| Dec 11, 2024 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 1,000 | $60.00 | $1.6B | -29.38% | +0.88% | $60.0K | -2.00% | 10b5-1 | Sell Now |
| Nov 26, 2024 | Sell | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 63,481 | $44.29 | $1.6B | -29.38% | +0.88% | $2.8M | -0.27% | — | Sell Now |
| Nov 15, 2024 | Sell | ANIP | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | 867 | $56.58 | $1.6B | -29.38% | +0.88% | $49.1K | -2.55% | — | Sell Now |
| Nov 15, 2024 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 6,500 | $57.70 | $1.6B | -29.38% | +0.88% | $375.1K | -7.81% | — | Sell Now |
| Nov 13, 2024 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 250 | $61.36 | $1.6B | -29.38% | +0.88% | $15.3K | -0.44% | 10b5-1 | Sell Now |
| Oct 14, 2024 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 250 | $57.19 | $1.6B | -29.38% | +0.88% | $14.3K | -0.44% | 10b5-1 | Sell Now |
| Sep 13, 2024 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 250 | $56.82 | $1.6B | -29.38% | +0.88% | $14.2K | -0.44% | 10b5-1 | Sell Now |
| Sep 12, 2024 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 1,486 | $56.15 | $1.6B | -29.38% | +0.88% | $83.4K | -2.88% | — | Sell Now |
| Sep 8, 2024 | Sell | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 3,646 | $60.51 | $1.6B | -29.38% | +0.88% | $220.6K | -0.97% | — | Sell Now |
| Aug 13, 2024 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 250 | $59.62 | $1.6B | -29.38% | +0.88% | $14.9K | -0.44% | 10b5-1 | Sell Now |
| Jul 18, 2024 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 1,743 | $61.35 | $1.6B | -29.38% | +0.88% | $106.9K | -2.96% | — | Sell Now |
| Jul 18, 2024 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 2,743 | $62.00 | $1.6B | -29.38% | +0.88% | $170.1K | -0.43% | 10b5-1 | Sell Now |
| Jul 15, 2024 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 47,257 | $63.73 | $1.6B | -29.38% | +0.88% | $3.0M | -2.36% | 10b5-1 | Sell Now |
| Jul 12, 2024 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 250 | $64.91 | $1.6B | -29.38% | +0.88% | $16.2K | -0.42% | 10b5-1 | Sell Now |
| Jul 1, 2024 | Sell | ANIP | Chad Gassert | SVP - CORP. DEV. & STRATEGY | 20,000 | $63.44 | $1.6B | -29.38% | +0.88% | $1.3M | -9.38% | 10b5-1 | Sell Now |
| Jun 21, 2024 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 20,000 | $58.90 | $1.6B | -29.38% | +0.88% | $1.2M | -2.85% | 10b5-1 | Sell Now |
| Jun 17, 2024 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 30,000 | $60.59 | $1.6B | -29.38% | +0.88% | $1.8M | -1.38% | 10b5-1 | Sell Now |
| Jun 13, 2024 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 250 | $63.80 | $1.6B | -29.38% | +0.88% | $15.9K | -0.42% | 10b5-1 | Sell Now |
| Jun 7, 2024 | Buy | ANIP | James G. Marken | SVP OPS & PROD DEV | 23,637 | $59.73 | $1.6B | -29.38% | +0.88% | $1.4M | +0.40% | — | Sell Now |
| Jun 5, 2024 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 2,985 | $67.00 | $1.6B | -29.38% | +0.88% | $200.0K | -3.72% | — | Sell Now |
| Jun 4, 2024 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 5,000 | $63.58 | $1.6B | -29.38% | +0.88% | $317.9K | -2.99% | — | Sell Now |
| Jun 3, 2024 | Sell | ANIP | Chad Gassert | SVP - CORP. DEV. & STRATEGY | 20,000 | $64.41 | $1.6B | -29.38% | +0.88% | $1.3M | -8.58% | 10b5-1 | Sell Now |
| May 21, 2024 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 2,000 | $61.61 | $1.6B | -29.38% | +0.88% | $123.2K | -2.35% | — | Sell Now |
| May 20, 2024 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 12,855 | $61.81 | $1.6B | -29.38% | +0.88% | $794.6K | -1.72% | 10b5-1 | Sell Now |
| May 15, 2024 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 37,145 | $64.37 | $1.6B | -29.38% | +0.88% | $2.4M | -1.61% | 10b5-1 | Sell Now |
| May 14, 2024 | Sell | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 16,669 | $66.10 | $1.6B | -29.38% | +0.88% | $1.1M | -4.23% | — | Sell Now |
| May 13, 2024 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 250 | $67.69 | $1.6B | -29.38% | +0.88% | $16.9K | -0.42% | 10b5-1 | Sell Now |
| May 1, 2024 | Sell | ANIP | Chad Gassert | SVP - CORP. DEV. & STRATEGY | 20,000 | $66.62 | $1.6B | -29.38% | +0.88% | $1.3M | -7.90% | 10b5-1 | Sell Now |
| Apr 18, 2024 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 27,232 | $65.10 | $1.6B | -29.38% | +0.88% | $1.8M | -1.69% | 10b5-1 | Sell Now |
| Apr 15, 2024 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 22,768 | $65.91 | $1.6B | -29.38% | +0.88% | $1.5M | -0.92% | 10b5-1 | Sell Now |
| Apr 12, 2024 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 250 | $67.79 | $1.6B | -29.38% | +0.88% | $16.9K | -0.42% | 10b5-1 | Sell Now |
| Apr 10, 2024 | Sell | ANIP | James G. Marken | SVP OPS & PROD DEV | 2,799 | $66.96 | $1.6B | -29.38% | +0.88% | $187.4K | -2.36% | — | Sell Now |
| Apr 10, 2024 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 4,534 | $66.96 | $1.6B | -29.38% | +0.88% | $303.6K | -2.64% | — | Sell Now |
| Apr 1, 2024 | Sell | ANIP | Chad Gassert | SVP - CORP. DEV. & STRATEGY | 20,000 | $67.25 | $1.6B | -29.38% | +0.88% | $1.3M | -7.32% | 10b5-1 | Sell Now |
| Mar 23, 2024 | Sell | ANIP | James G. Marken | SVP OPS & PROD DEV | 3,653 | $69.58 | $1.6B | -29.38% | +0.88% | $254.2K | -2.98% | — | Sell Now |
| Mar 23, 2024 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 6,210 | $69.58 | $1.6B | -29.38% | +0.88% | $432.1K | -3.49% | — | Sell Now |
| Mar 23, 2024 | Sell | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 17,455 | $69.58 | $1.6B | -29.38% | +0.88% | $1.2M | -4.24% | — | Sell Now |
| Mar 13, 2024 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 250 | $66.54 | $1.6B | -29.38% | +0.88% | $16.6K | -0.42% | 10b5-1 | Sell Now |
| Mar 11, 2024 | Sell | ANIP | Chad Gassert | SVP - CORP. DEV. & STRATEGY | 20,000 | $65.81 | $1.6B | -29.38% | +0.88% | $1.3M | -6.82% | 10b5-1 | Sell Now |
| Mar 8, 2024 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 10,000 | $67.17 | $1.6B | -29.38% | +0.88% | $671.7K | -1.19% | 10b5-1 | Sell Now |
| Mar 7, 2024 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 2,110 | $66.71 | $1.6B | -29.38% | +0.88% | $140.8K | -2.41% | — | Sell Now |
| Mar 7, 2024 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 2,494 | $66.71 | $1.6B | -29.38% | +0.88% | $166.4K | -3.02% | — | Sell Now |
| Mar 7, 2024 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 12,003 | $65.96 | $1.6B | -29.38% | +0.88% | $791.7K | -3.20% | — | Sell Now |
| Mar 7, 2024 | Sell | ANIP | James G. Marken | SVP OPS & PROD DEV | 26,372 | $66.40 | $1.6B | -29.38% | +0.88% | $1.8M | -9.65% | — | Sell Now |
| Mar 6, 2024 | Sell | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 62,317 | $66.27 | $1.6B | -29.38% | +0.88% | $4.1M | -4.63% | — | Sell Now |
| Mar 5, 2024 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 5,000 | $66.00 | $1.6B | -29.38% | +0.88% | $330.0K | -5.41% | — | Sell Now |
| Mar 5, 2024 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 40,000 | $65.77 | $1.6B | -29.38% | +0.88% | $2.6M | -1.53% | 10b5-1 | Sell Now |
| Feb 29, 2024 | Sell | ANIP | James G. Marken | SVP OPS & PROD DEV | 1,058 | $67.67 | $1.6B | -29.38% | +0.88% | $71.6K | -0.71% | — | Sell Now |
| Feb 29, 2024 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 1,122 | $67.67 | $1.6B | -29.38% | +0.88% | $75.9K | -1.61% | — | Sell Now |
| Feb 29, 2024 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 1,173 | $67.67 | $1.6B | -29.38% | +0.88% | $79.4K | -1.91% | — | Sell Now |
| Feb 29, 2024 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 1,173 | $67.67 | $1.6B | -29.38% | +0.88% | $79.4K | -2.23% | — | Sell Now |
| Feb 29, 2024 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 1,275 | $67.67 | $1.6B | -29.38% | +0.88% | $86.3K | -1.36% | — | Sell Now |
| Feb 29, 2024 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 1,570 | $67.67 | $1.6B | -29.38% | +0.88% | $106.2K | -1.86% | — | Sell Now |
| Feb 29, 2024 | Sell | ANIP | Chad Gassert | SVP - CORP. DEV. & STRATEGY | 1,635 | $67.67 | $1.6B | -29.38% | +0.88% | $110.6K | -3.19% | — | Sell Now |
| Feb 29, 2024 | Sell | ANIP | Stephen P. Carey | SVP & CFO | 1,914 | $67.67 | $1.6B | -29.38% | +0.88% | $129.5K | -1.00% | — | Sell Now |
| Feb 29, 2024 | Sell | ANIP | Nikhil Lalwani | PRESIDENT & CEO | 10,014 | $67.67 | $1.6B | -29.38% | +0.88% | $677.6K | -2.07% | — | Sell Now |
| Feb 15, 2024 | Sell | ANIP | Ori Gutwerg | SVP, GENERICS | 1,244 | $57.55 | $1.6B | -29.38% | +0.88% | $71.6K | -1.45% | — | Sell Now |
| Feb 15, 2024 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 1,261 | $57.55 | $1.6B | -29.38% | +0.88% | $72.6K | -1.33% | — | Sell Now |
| Feb 13, 2024 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 250 | $56.04 | $1.6B | -29.38% | +0.88% | $14.0K | -0.67% | 10b5-1 | Sell Now |
| Jan 19, 2024 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 25,216 | $56.17 | $1.6B | -29.38% | +0.88% | $1.4M | -0.93% | 10b5-1 | Sell Now |
| Jan 16, 2024 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 24,784 | $55.29 | $1.6B | -29.38% | +0.88% | $1.4M | -0.89% | 10b5-1 | Sell Now |
| Jan 12, 2024 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 250 | $56.43 | $1.6B | -29.38% | +0.88% | $14.1K | -0.67% | 10b5-1 | Sell Now |
| Dec 15, 2023 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 50,000 | $52.55 | $1.6B | -29.38% | +0.88% | $2.6M | -1.72% | 10b5-1 | Sell Now |
| Dec 11, 2023 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 250 | $49.21 | $1.6B | -29.38% | +0.88% | $12.3K | -0.67% | 10b5-1 | Sell Now |
| Nov 17, 2023 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 13,000 | $51.00 | $1.6B | -29.38% | +0.88% | $663.0K | -1.31% | 10b5-1 | Sell Now |
| Nov 15, 2023 | Sell | ANIP | Krista Davis | SVP, CHIEF HR OFFICER | 2,622 | $53.81 | $1.6B | -29.38% | +0.88% | $141.1K | -7.45% | — | Sell Now |
| Nov 14, 2023 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 36,190 | $53.00 | $1.6B | -29.38% | +0.88% | $1.9M | -1.19% | 10b5-1 | Sell Now |
| Nov 14, 2023 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 37,000 | $53.00 | $1.6B | -29.38% | +0.88% | $2.0M | -1.22% | 10b5-1 | Sell Now |
| Nov 13, 2023 | Sell | ANIP | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 250 | $52.03 | $1.6B | -29.38% | +0.88% | $13.0K | -0.66% | 10b5-1 | Sell Now |
| Nov 10, 2023 | Sell | ANIP | Christopher Mutz | HEAD OF RARE DISEASE | 3,000 | $52.47 | $1.6B | -29.38% | +0.88% | $157.4K | -4.50% | — | Sell Now |
| Oct 17, 2023 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 25,000 | $57.75 | $1.6B | -29.38% | +0.88% | $1.4M | -0.79% | 10b5-1 | Sell Now |
| Oct 13, 2023 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 25,000 | $57.96 | $1.6B | -29.38% | +0.88% | $1.4M | -1.16% | 10b5-1 | Sell Now |
| Oct 2, 2023 | Sell | ANIP | Chad Gassert | SVP - CORP. DEV. & STRATEGY | 20,000 | $56.48 | $1.6B | -29.38% | +0.88% | $1.1M | -6.39% | 10b5-1 | Sell Now |
| Sep 15, 2023 | Sell | ANIP | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 50,000 | $61.81 | $1.6B | -29.38% | +0.88% | $3.1M | -1.49% | 10b5-1 | Sell Now |